← All trials
NCT04030988
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2018
- Primary completion
- Sep 30, 2019
- Completion date
- Nov 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityOverall official - principal investigator
- Ain Shams UniversityReponsible party - principal investigator
- Alexandria UniversityCollaborator
- Cairo UniversityCollaborator
- Assiut UniversityCollaborator
- Suez Canal UniversityCollaborator
- Menia UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.